Skip to content

News

Maintenance Pazopanib in Ovarian Cancer: No Survival Benefi...

Maintenance Pazopanib in Ovarian Cancer: No Survival Benefit, High Rate of Complications

(Sept. 25, 2014) Maintenance therapy with the oral agent pazopanib improved progression free survival (PFS) by a median of 5.6 months in patients with advanced ovarian cancer but did not impact overall survival, according to the results of a phase III randomized trial reported in the Journal of Clinical Oncology. In this clinical trial, which … Continued

OCRF Research Finds Metastasis Promoted by Mesothelial Cells

OCRF Research Finds Metastasis Promoted by Mesothelial Cells

A new study in the Journal of Clinical Investigation indicates that mesothelial cells actively promote the spread of ovarian cancer. Using a three dimensional culture model of ovarian cancer metastasis, OCRF grantee and Scientific Advisory Committee Member Ernst Lengyel, MD, PhD, and colleagues at the Unviersity of Chicago found that in the presence of cancer … Continued

Call for Ideas Now Open for the Ovarian Cancer Translationa...

Call for Ideas Now Open for the Ovarian Cancer Translational Research Dream Team Grant

A Collaboration of Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition PHILADELPHIA — The American Association for Cancer Research (AACR) is now accepting submissions of ideas for the Stand Up To Cancer (SU2C)-Ovarian Cancer Research Fund (OCRF)-Ovarian Cancer National Alliance (OCNA)-National Ovarian Cancer Coalition (NOCC) Translational … Continued

Ovarian Cancer Dream Team Call for Ideas Now Open

Ovarian Cancer Dream Team Call for Ideas Now Open

The American Association for Cancer Research is now accepting submissions of ideas for the new Stand Up To Cancer Ovarian Cancer Translational Research Dream Team Grant that will offer up to $6 million in research funding, which includes $3 million provided by the leading funder, OCRF. The Stand Up To Cancer-Ovarian Cancer Research Fund-Ovarian Cancer … Continued

New Study Shows No Association between Powder Use and Ovari...

New Study Shows No Association between Powder Use and Ovarian Cancer

(September 12, 2014) A new study published in the Journal of the National Cancer Institute this month suggests that use of perineal powder does not influence ovarian cancer risk. In the past, some studies have suggested that there is an increased risk of ovarian cancer among talc users.  In this new and large prospective study, … Continued

New Stand Up To Cancer Ovarian Cancer Dream Team Announced

New Stand Up To Cancer Ovarian Cancer Dream Team Announced

Ovarian Cancer Community Joins Forces to Fight Deadliest Gynecologic Cancer A groundbreaking collaboration among three national ovarian cancer organizations was announced during the Stand Up to Cancer telecast on Friday evening, September 5th. Ovarian Cancer Research Fund (OCRF), Ovarian Cancer National Alliance (OCNA), and National Ovarian Cancer Coalition (NOCC) have teamed up with Stand Up … Continued

Statin Therapy and Improved Survival in Some Ovarian Cancer...

Statin Therapy and Improved Survival in Some Ovarian Cancer Patients

(September 2, 2014) New research by researchers at the University of Chicago, including OCRF grantee and Scientific Advisory Committee member Ernst Lengyel, MD, PhD, investigated whether statin use is associated with improved epithelial ovarian cancer (OvCa) survival.  The findings were published this month in PLoS One. The use of statins to lower cholesterol as a … Continued

Dietary Fat Intake and Risk of Epithelial Ovarian Cancer

Dietary Fat Intake and Risk of Epithelial Ovarian Cancer

(August 27, 2014) Recent research published in Cancer Epidemiology suggests that there is “no association with consumption of total fat, animal or plant fat, saturated fat, cholesterol, monounsaturated fat, or fatty fish and risk of invasive epithelial ovarian cancer.” An international team of researchers was interested in assessing the relationship between fat intake and risk … Continued

New Report Recommends Classifying Cancer by Genetic and Mol...

New Report Recommends Classifying Cancer by Genetic and Molecular Type

(August 21, 2014) A research network in the US proposes that cancer should be classified according to genetic and molecular features rather than by the type of tissue in which the tumor arises. While more work is needed to confirm and build on the findings, the scientists say such a system would be better for … Continued

Drug Combination Impacts Outcomes in Ovarian Cancer Patient...

Drug Combination Impacts Outcomes in Ovarian Cancer Patients without BRCA Mutations

BRCA mutations in ovarian cancer are a double-edged sword.  While BRCA gene mutation carriers have a significantly higher risk of developing ovarian cancer, BRCA gene mutation in tumors is associated with a significant increase in patient survival.  Scientists believe that this is because loss of BRCA gene expression leads to an increase tumor cell response … Continued

Epigenetic Targeting of Ovarian Cancer Stem Cells

Epigenetic Targeting of Ovarian Cancer Stem Cells

(July 29, 2014)   OCRF-funded research published earlier this month provides the first proof of principle that epigenomic strategies efficiently target ovarian cancer stem cells, which are key for treatment resistance and the major factor in therapy failures.  OCRF grantees Kenneth Nephew, PhD and Daniela Matei, MD are first and senior author of the paper, which was … Continued

Most High Risk Women Aren't Aware of Ovarian Cancer Risk

Most High Risk Women Aren't Aware of Ovarian Cancer Risk

(July 28, 2014) Research published last week in Behavioral Medicine suggests that most high-risk women (>75%) do not know their risk for ovarian cancer. Women with a documented deleterious mutation in BRCA1 or BRCA2 are at substantially elevated risk for ovarian cancer. To understand what percentage of women with high risk family histories know their … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.